CML PocketCard 2013

Based on the recent publication of the 2013 European LeukemiaNet recommendations for the management of chronic myeloid leukemia the CML pocket card was updated. The new pocket card in PDF format and the related order form are now available online. ▶ CML PocketCard 2013

ELN mid-term report for the European Science Foundation (ESF)

From July 2010 to June 2015, the European LeukemiaNet is funded through a research networking programme initiated by the ESF. The mid-term report summarizing ELN’s activities of the past three years was recently submitted to the ESF. The report can now be downloaded from the website. ▶ mid-term report

ELN guidelines and recommendations

The most visible results of the ELN are the guidelines and management recommendations for virtually every leukemia and interdisciplinary speciality which have lain the groundwork for uniform definitions and standards required for common clinical trials and projects. An update of the collection of the ELN guidelines and recommendations developed since 2006 is now available. ▶ collection of ELN guidelines and recommendations

Update of WP participants

On a half-yearly basis the contact data of active WP participants are updated on the website. The most recent lists as well as short overviews of the respective lead participants are online now. Please find these lists including the participant’s organization, nationality and e-mail address in the section “contact” of every workpackage. ▶ contact NMC for changes

Publications from the Network (selected)

Acute lymphoblastic leukemia

▶ Gökbuget N. How I treat older patients with ALL. Blood. 2013 Aug 22;122(8):1366-75.

Acute myeloid leukemia

▶ Grossmann V et al. Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based
on cytogenetic and molecular genetic characteristics. Leukemia. 2013 Sep;27(9):1940-3.


**Chronic myeloid leukemia**


**Chronic lymphocytic leukemia**


Schnaiter A et al. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood. 2013 Aug 15;122(7):1266-70.

Myelodysplastic syndromes


Myeloproliferative neoplasms


Myelodysplastic/Myeloproliferative neoplasms

Broséus J et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013 Sep;27(9):1826-31.

Meggendorfer M et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013 Sep;27(9):1852-60.

Diagnostics


Stem cell transplantation


Infectious diseases


New trials in the ELTR

- **CHOICES** A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction (Q-PCR)
- **B1931022** An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator’s Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
- **PEGASY** Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)